The Law Offices of Frank R. Cruz announces an investigation of Grail, Inc. (“Grail” or the “Company”) (NASDAQ: GRAL) on behalf of investors concerning the Company’s possible violations of federal securities laws.

What Is The Investigation About?
On February 19, 2026, Grail announced that the “primary endpoint of statistically significant Stage III-IV [cancer] reduction was not observed” in its NHS-Galleri Trial due, in part, to “probably need[ing] a longer follow-up time to be able to [compare the study arms] adequately.”

On this news, Grail’s stock price fell $51.32, or 50.5%, to close at $50.21 per share on February 20, 2026, thereby inuring investors.